文献速递糖尿病

更快门冬胰岛素与门冬胰岛素作为基础-餐时方案组成部分在控制不佳的2型糖尿病中的比较:onset 2试验

Faster Aspart Versus Insulin Aspart as Part of a Basal-Bolus Regimen in Inadequately Controlled Type 2 Diabetes: The onset 2 Trial.
PubMed 文献 · Diabetes Care · 2017-05-08

这项多中心、双盲、达标治疗、3期试验比较更快门冬胰岛素与门冬胰岛素在成人2型糖尿病中的疗效与安全性。主要终点为治疗26周后HbA1c自基线变化,更快门冬胰岛素非劣于门冬胰岛素,1小时餐后血糖增量更优,总体低血糖率相似但餐后0-2小时低血糖率增加。

要点

  • 更快门冬胰岛素在降低HbA1c方面非劣于门冬胰岛素。
  • 更快门冬胰岛素1小时餐后血糖增量优于门冬胰岛素。
  • 更快门冬胰岛素餐后0-2小时低血糖率高于门冬胰岛素。

核心结论

  • 更快门冬胰岛素与门冬胰岛素在基础-餐时方案中关于HbA1c自基线变化被确认为非劣效。
  • 更快门冬胰岛素改善1小时餐后血糖,2-4小时餐后血糖与门冬胰岛素无差异。
  • 总体低血糖率相似,但更快门冬胰岛素餐后0-2小时低血糖增加。

研究设计与样本

  • 多中心、双盲、达标治疗、3期试验。
  • 成人2型糖尿病受试者接受基础胰岛素和口服降糖药。
  • 经8周导入期优化基础胰岛素后,按1:1随机至更快门冬胰岛素组(n=345)或门冬胰岛素组(n=344)。
  • 主要终点为治疗26周后HbA1c自基线变化。

主要发现

  • HbA1c变化:更快门冬胰岛素组-1.38%,门冬胰岛素组-1.36%;两组平均HbA1c均为6.6%。
  • HbA1c降低的非劣效性:估计治疗差异(ETD)[95% CI] -0.02% [-0.15; 0.10]。
  • 液体餐试验1小时餐后血糖增量:ETD [95% CI] -0.59 mmol/L [-1.09; -0.09](-10.63 mg/dL [-19.56; -1.69]),P=0.0198。
  • 空腹血糖、体重和总体严重/血糖确证低血糖率变化:率比(RR)[95% CI] 1.09 [0.88; 1.36],两组相似。
  • 餐后0-2小时低血糖率:更快门冬胰岛素组2.27例/患者-年暴露,门冬胰岛素组1.49例/患者-年暴露;RR [95% CI] 1.60 [1.13; 2.27]。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This multicenter, double-blind, treat-to-target, phase 3 trial evaluated the efficacy and safety of fast-acting insulin aspart (faster aspart) versus insulin aspart (IAsp) in adults with type 2 diabetes receiving basal insulin and oral antidiabetic agents. RESEARCH DESIGN AND METHODS: The primary end point was HbA1c change from baseline after 26 weeks' treatment. After an 8-week run-in to optimize basal insulin, subjects were randomized (1:1) to mealtime faster aspart (n = 345) or IAsp (n = 344), titrated using a simple daily patient-driven algorithm, plus insulin glargine U100 and metformin. RESULTS: HbA1c change was -1.38% (faster aspart) and -1.36% (IAsp); mean HbA1c was 6.6% for both groups. Faster aspart demonstrated noninferiority versus IAsp in reducing HbA1c (estimated treatment difference [ETD] [95% CI] -0.02% [-0.15; 0.10]). Both treatments improved postprandial plasma glucose (PPG) control; the PPG increment (liquid meal test) was statistically significant in favor of faster aspart after 1 h (ETD [95% CI] -0.59 mmol/L [-1.09; -0.09]; -10.63 mg/dL [-19.56; -1.69]; P = 0.0198), but not after 2-4 h. Change from baseline in fasting plasma glucose, body weight, and overall severe/blood glucose-confirmed hypoglycemia rates (rate ratio [RR] [95% CI] 1.09 [0.88; 1.36]) were similar between treatments. Postmeal hypoglycemia (0-2 h) rates were 2.27 (faster aspart) and 1.49 (IAsp) per patient-year of exposure (RR [95% CI] 1.60 [1.13; 2.27]). CONCLUSIONS: Faster aspart and IAsp were confirmed noninferior in a basal-bolus regimen regarding change from baseline in HbA1c. Faster aspart improved 1-h PPG with no differences in 2-4-h PPG versus IAsp. Overall hypoglycemia rates were similar except for an increase in 0-2-h postmeal hypoglycemia with faster aspart.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Bowering K, Case C, Harvey J, et al. Faster Aspart Versus Insulin Aspart as Part of a Basal-Bolus Regimen in Inadequately Controlled Type 2 Diabetes: The onset 2 Trial. Diabetes Care. 2017. PMID: 28483786. doi:10.2337/dc16-1770

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。